Cargando…
Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer
OBJECTIVES: The prostate cancer gene 3 (PCA3), human kallikrein 2, and miRNA-141 are promising prostate cancer (Pca) specific biomarkers. Our aim was to evaluate the detection of PCA3, human glandular kallikrein 2 (hk2), and miRNA-141 mRNA in peripheral blood of patients received prostate biopsy. Wh...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211911/ https://www.ncbi.nlm.nih.gov/pubmed/30334974 http://dx.doi.org/10.1097/MD.0000000000012806 |
_version_ | 1783367431651065856 |
---|---|
author | Mao, Zujie Ji, Alin Yang, Kebing He, Wei Hu, Yingfang Zhang, Qi Zhang, Dahong Xie, Liping |
author_facet | Mao, Zujie Ji, Alin Yang, Kebing He, Wei Hu, Yingfang Zhang, Qi Zhang, Dahong Xie, Liping |
author_sort | Mao, Zujie |
collection | PubMed |
description | OBJECTIVES: The prostate cancer gene 3 (PCA3), human kallikrein 2, and miRNA-141 are promising prostate cancer (Pca) specific biomarkers. Our aim was to evaluate the detection of PCA3, human glandular kallikrein 2 (hk2), and miRNA-141 mRNA in peripheral blood of patients received prostate biopsy. What's more, we want to detect the value of combination of PSA (prostate specific antigen) in the early diagnosis of PCa. MATERIALS AND METHODS: Hundred patients were divided into 2 groups according to the results of pathologic diagnosis. Quantitative real-time PCR (qRT-PCR) was used to evaluate the mRNA of PCA3, hk2, and miRNA-141 in peripheral blood. At the same time, analyze those clinical outcomes used in the patients. We compared these different outcomes to evaluate the value of new molecular markers. RESULTS: The level of mRNA of PCA3, hK2, and miR-141 in Pca group were significantly higher than that in BPH. PSA had the highest sensitivity in predicting Pca diagnosis (76.7%); PCA3 had the highest specificity (82.5%). And the combination of PCA3, PSA, and hK2 improved area under the curve (AUC)-receiver operating characteristic (ROC) curve largely, especially those with PSA 4-10ng/mL. CONCLUSIONS: PCA3, hK2, and miRNA-141 were biomarkers of Pca with potential clinical application value, especially in patients with PSA gray area. Combining PCA3, PSA, and hK2 performed better than individual biomarkers alone in predicting Pca. |
format | Online Article Text |
id | pubmed-6211911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-62119112018-11-27 Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer Mao, Zujie Ji, Alin Yang, Kebing He, Wei Hu, Yingfang Zhang, Qi Zhang, Dahong Xie, Liping Medicine (Baltimore) Research Article OBJECTIVES: The prostate cancer gene 3 (PCA3), human kallikrein 2, and miRNA-141 are promising prostate cancer (Pca) specific biomarkers. Our aim was to evaluate the detection of PCA3, human glandular kallikrein 2 (hk2), and miRNA-141 mRNA in peripheral blood of patients received prostate biopsy. What's more, we want to detect the value of combination of PSA (prostate specific antigen) in the early diagnosis of PCa. MATERIALS AND METHODS: Hundred patients were divided into 2 groups according to the results of pathologic diagnosis. Quantitative real-time PCR (qRT-PCR) was used to evaluate the mRNA of PCA3, hk2, and miRNA-141 in peripheral blood. At the same time, analyze those clinical outcomes used in the patients. We compared these different outcomes to evaluate the value of new molecular markers. RESULTS: The level of mRNA of PCA3, hK2, and miR-141 in Pca group were significantly higher than that in BPH. PSA had the highest sensitivity in predicting Pca diagnosis (76.7%); PCA3 had the highest specificity (82.5%). And the combination of PCA3, PSA, and hK2 improved area under the curve (AUC)-receiver operating characteristic (ROC) curve largely, especially those with PSA 4-10ng/mL. CONCLUSIONS: PCA3, hK2, and miRNA-141 were biomarkers of Pca with potential clinical application value, especially in patients with PSA gray area. Combining PCA3, PSA, and hK2 performed better than individual biomarkers alone in predicting Pca. Wolters Kluwer Health 2018-10-19 /pmc/articles/PMC6211911/ /pubmed/30334974 http://dx.doi.org/10.1097/MD.0000000000012806 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | Research Article Mao, Zujie Ji, Alin Yang, Kebing He, Wei Hu, Yingfang Zhang, Qi Zhang, Dahong Xie, Liping Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer |
title | Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer |
title_full | Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer |
title_fullStr | Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer |
title_full_unstemmed | Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer |
title_short | Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer |
title_sort | diagnostic performance of pca3 and hk2 in combination with serum psa for prostate cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211911/ https://www.ncbi.nlm.nih.gov/pubmed/30334974 http://dx.doi.org/10.1097/MD.0000000000012806 |
work_keys_str_mv | AT maozujie diagnosticperformanceofpca3andhk2incombinationwithserumpsaforprostatecancer AT jialin diagnosticperformanceofpca3andhk2incombinationwithserumpsaforprostatecancer AT yangkebing diagnosticperformanceofpca3andhk2incombinationwithserumpsaforprostatecancer AT hewei diagnosticperformanceofpca3andhk2incombinationwithserumpsaforprostatecancer AT huyingfang diagnosticperformanceofpca3andhk2incombinationwithserumpsaforprostatecancer AT zhangqi diagnosticperformanceofpca3andhk2incombinationwithserumpsaforprostatecancer AT zhangdahong diagnosticperformanceofpca3andhk2incombinationwithserumpsaforprostatecancer AT xieliping diagnosticperformanceofpca3andhk2incombinationwithserumpsaforprostatecancer |